share_log

Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4

Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4

联盟全球合作伙伴维持对Pluristem Therapeutics的买入,将目标股价下调至4美元
Benzinga Real-time News ·  2022/07/20 09:24

Alliance Global Partners analyst James Molloy maintains Pluristem Therapeutics (NASDAQ:PSTI) with a Buy and lowers the price target from $9.5 to $4.

Alliance Global Partners分析师詹姆斯·莫洛伊维持Pluristem Therapeutics(纳斯达克股票代码:PSTI)的买入,并将目标股价从9.5美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发